1. Saad SY, Najjar TA, Al-Rikabi AC. The preventive role
deferoxamine against acute doxorubicin-induced cardiac,
renal and hepatic toxicity in rats. Pharmacol Res
2001; 43: 211-218.
2. Akkufl ‹. Serbest Radikaller ve fizyopatolojik etkileri.
Konya: Mimoza Yay›nlar›; 1995.
3. Kavas (Özelçi) G. Serbest radikaller ve organizma
üzerine etkileri. Türkiye Klinikleri 1989; 9: 1-8.
4. Meram ‹., Aktaran fi. Serbest radikallerin biyomoleküller
üzerine etkileri. Arfliv 2002; 1: 299-304.
5. Ya¤murca A, Bas O, Mollaoglu H, et al. Protective
effects of erdosteine on doxorubicin-induced hepatotoxicity
in rats. Arch Med Res 2007; 38: 380-385.
6. Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K.
Anthracycline-induced cardiotoxicity: clinical course,
risk factors, pathogenesis, detection and prevention
review of the literature. Med Sci Monit 2000; 6: 411-
412.
7. Tanr›verdi G. Karbon tetraklorür (CCL4) ile oluflturulmufl
karaci¤er hasar›nda de¤iflik dozlardaki nikotinamidin
protektif etkisinin ›fl›k ve elektron mikroskobik
olarak incelenmesi [Yüksek Lisans Tezi]. ‹stanbul:
‹.Ü.Cerrahpafla T›p Fakültesi Histoloji ve Embriyoloji
A.D.; 2005.
8. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D, et al.
Antioxidant therapy: a new pharmacological approach
in shock, inflammation, and ischemia/reperfusion
injury. Pharmacol Rev 2001; 53: 135-159.
9. Damc› T. Koruyucu giriflimler. Diabetes Mellitus Sempozyumu.
‹stanbul; 151-156.
10. Beutler E, Blurne KG, Kaplan JC, et al. International
Comitte for Standardization in Haematology: Recommended
methods for red blood cell enzyme analysis.
Br J Haematol 1977; 35: 331-340.
11. Habig WH, Pabst MJ, Jacob WB. Glutathione-S-transferase.
The first enzymatic step in mercapturic acid
formation. J Biol Chem 1974; 249: 7130-7139.
12. Aebi H. Catalase. In: Bergmeyer H.U, ed. Metods of
enzymatic analysis. Newyork: Academic Press; 1974;
673-677.
13. Levine RL, Garland D, Oliver CV, et al. Determination
of carbonyl content in oxidatively modified proteins.
Meth Enzymol 1990; 186: 464-473.
14. Kayaalp O. Rasyonel tedavi yönünden t›bbi farmakoloji.
Ankara: Günefl Bas›mevi; 2000; 1011-1013.
15. Singal PK, Iliskovic N, Kumar D. Adriamycin cardiomyopathy:
pathophysiology and prevention. FASEB J
1997; 11: 931-936.
16. el-Shazly MO, Afify MM, el-Dieb MK. Histopathological
study into side-effect toxicity of some drugs used
in treatment of cancer. Arch Exp Veterinarmed 1989;
43: 319-326.
17. Fadillioglu E, Oztas E, Erdo¤an H, et al. protective effects
of caffeic acid phenethyl ester on doxorubicininduced
cardiotoxicity in rats. J Appl Toxicol 2004;
24: 47-52
18. Sacco G, Bigio M, Evangelista S, et al. Cardioprotective
effects of zofenopril, a new angiotensin-converting
enzyme inhibitor, on doxorubicin-induced cardiotoxicity
in the rat. Eur J Pharmacol 2001; 414: 71-78.
Cerrahpafla T›p Derg 2008; 39(1): 7-14
19. Venditti P, Balestrieri M, De Leo T, Di Meo S. Free
radical involvement in doxorubucin-induced electrophysiological
alterations in rat papillary muscle fibres.
Cardiovasc Res 1998; 38: 695-702.
20. Siveski-‹liskovic N, Kaul N, Signal PK. Probucol prometes
endogenous antioxidants and provides protection
against adriamycin-induced cardiomyopathy in
rats. Circulation 1994; 89: 2829-2835.
21. Sadzuka Y, Sugiyama T, Shimoi K, et al. Protective effect
of flavonoids on doxorubicin-induced cardiotoxicity.
Toxicol Lett 1997; 92: 1-7.
22. Myers C. The role of iron in doxorubicin-induced cardiomyopathy.
Semin Oncol 1998; 25: 10-14.
23. Malarkodi PK, Balachandar AV, Varalakshmi P. Protective
effect of lipoic acid on adriamycin induced lipid
peroxidation in rat kidney. Mol Cell Biochem
2003; 247: 9-13.
24. Tesoriene L, Ciaccio M, Valenza M, et al. Effect of vitamin
A administration on resistance of rat heart against
doxorubicin-induced cardiotoxicity and lethality.
J Pharm Exp Ther 1994; 269: 430-6.
25. Van Vlett JF, Ferrans VJ, Weirich WE. Cardiac disease
induced by chronic adriamycin administration in
dogs and an evaluation of vitamin E and selenium as
cardioprotectants. Am J Pathol 1980; 99: 13-42.
26. Balli E, Mete ÖU, Tuli A, et al. Effect of melatonin on
the cardiotoxicity of doxorubicin. Histol Histopatol
2004; 19: 1101-1108.
27. Ungersted JS, Blömback M, Söderström T. Nicotinamide
is a potent inhibitor of proinflammatory cytokines.
Clin Exp Immunol 2003; 131: 48-52.
28. Fukuzawa M, Satoh J, Muto G, et al. ‹nhibitory effect
of nicotinamide on in vitro and in vivo production of
tumor necrosis factor-alpha. Immunol Lett 1997; 59:
7-11.
Thank you for copying data from http://www.arastirmax.com
